Ian Weir, DO
Pulmonary Disease · Norwalk, CTNPI 1548368293
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,324 of the $3,202 with a category attached, or 72.6%. It is spread thinly across 22 manufacturers, the largest accounting for just 16.9%.
Across 74 payments — averaging $43.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$541
- Olympus Corporation Of The Americas$465
- Jazz Pharmaceuticals Inc.$317
- Boehringer Ingelheim$287
- Avadel CNS Pharmaceuticals, LLC$230
- Harmony Biosciences LLC$195
- plus $1K from 16 others
Across 13 payments — averaging $3734.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Harmony Biosciences LLC$49K
What the payments were for
- Consulting fees$35011%
- Travel & lodging$35811%
- Food & beverage$2,32473%
- Education$1705%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $541 |
| Olympus Corporation Of The Americas | 4 | $465 |
| Jazz Pharmaceuticals Inc. | 4 | $317 |
| Boehringer Ingelheim | 11 | $287 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $230 |
| Harmony Biosciences LLC | 3 | $195 |
| Sanofi | 6 | $190 |
| Amgen | 3 | $162 |
| Inari Medical, Inc. | 1 | $144 |
| Regeneron Healthcare Solutions, Inc. | 3 | $138 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Verona Pharma, Inc. | 3 | $72 |
| Lilly USA, LLC | 4 | $66 |
| Merck | 3 | $59 |
| Insmed, Inc. | 3 | $58 |
| ZOLL Respicardia, Inc. | 1 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| GSK | 1 | $28 |
| Grifols USA, LLC | 1 | $27 |
| Bristol Myers Squibb | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Electromed, Inc. | 2 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,202 in reported general payments places this provider in the 65th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $49,795 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 64 | $46,340 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $10,732 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $1,862 |
| Modafinil | 14 | $1,102 |
| Montelukast Sodium | 11 | $201 |
| Zolpidem Tartrate | 24 | $186 |
| Eszopiclone | 12 | $101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $28 | $96,135107 claims |
| Boehringer IngelheimStiolto Respimat | $287 | $10,73219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in Norwalk
- Geoffrey ChuppNew Haven$1.2M
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Michael ImevboreNew Haven$323K
- Jeffrey NascimentoHartford$213K
- Thinesh DahanayakeNorwich$192K
- Naftali KaminskiNew Haven$180K
- Daniel GerardiHartford$156K
- Roman SpivakAnsonia$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.